|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Tony Sampognaro of Stoke Therapeutics, says, “We're having to rearrange and bolster the constellation of CDMOs we're working with." The nice thing is, Stoke has a comprehensive extended enterprise model. Nonetheless, an all-outsourced model “can add hidden complexity." Here's how to manage that. | |
|
|
|
|
|
|
Ensuring The Efficacy Of Probiotic Products | Article | Ropack Pharma Solutions | Without proper handling and packaging, the efficacy of probiotics can be compromised at any point in the packaging, storage, and transportation process, impacting shelf life and effectiveness. |
|
|
|
|
|
|
Molecule To Cure. Fast. | Quotient Sciences | Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast. |
|
|
|
Capacity Update January 2025: Small Molecule | Alcami | With cutting-edge capabilities and client-focused solutions, we support your drug development journey from concept to commercialization, bringing transformative therapies to patients with speed and quality. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
Connect With Outsourced Pharma: |
|
|
|